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Abstract
Great efforts have been made to develop novel and efficacious therapeutics against pancreatic cancer to improve the
treatment outcomes. Tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) is such a therapeutic cytokine with
selective killing effect toward malignant cells. However, some human pancreatic cancers are intrinsically resistant to TRAIL-
mediated apoptosis or therapy. In this study, we have shown that the histone deacetylase inhibitor LBH589 can synergize
with TRAIL to augment apoptosis even in TRAIL-resistant cells. LBH589 decreased c-FLIP levels in every tested cell line and
survivin levels in some of the tested cell lines. Enforced expression of ectopic c-FLIP, but not survivin, abolished the
cooperative induction of apoptosis by the combination of LBH589 and TRAIL, indicating that c-FLIP downregulation plays a
critical role in LBH589 sensitization of pancreatic cancer cells to TRAIL. Moreover, LBH589 decreased c-FLIP stability and the
presence of the proteasome inhibitor MG132 prevented c-FLIP from reduction by LBH589. Correspondingly, we detected
increased levels of ubiqutinated c-FLIP in LBH589-treated cells. These data thus indicate that LBH589 promotes ubiqutin/
proteasome-mediated degradation of c-FLIP, leading to downregulation of c-FLIP. Collectively, LBH589 induces c-FLIP
degradation and accordingly sensitizes pancreatic cancer cells to TRAIL-induced apoptosis, highlighting a novel therapeutic
regimen against pancreatic cancer.
Citation: Kauh J, Fan S, Xia M, Yue P, Yang L, et al. (2010) c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the
Histone Deacetylase Inhibitor LBH589. PLoS ONE 5(4): e10376. doi:10.1371/journal.pone.0010376
Editor: Dong-Yan Jin, University of Hong Kong, Hong Kong
Received March 12, 2010; Accepted April 7, 2010; Published April 28, 2010
Copyright:  2010 Kauh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Georgia Cancer Coalition Distinguished Cancer Scholar award (to S-Y. S.) and departmental research fund (to J. K.). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ssun@emory.edu
Introduction
Pancreatic cancer is one of the most difficult cancers to treat
although it accounts for only 3% of all cancers. Despite multiple
clinical trials with new chemotherapeutic agents, over the past 25
years the 5-year survival rate of 5%, and median survival of 6
months has largely remained unchanged. The median survival is
about 6 months [1,2]. One reason for the poor survival of
pancreatic cancer is the insensitivity to most conventional
therapies including chemotherapy and radiotherapy [3]. Thus,
novel and efficacious therapeutic agents or regimens are urgently
needed for treatment of pancreatic cancer.
Apoptosis is an essential part of mechanisms that maintain
normal tissue homeostasis [4]. Deregulation of the apoptosis
machinery and evasion of apoptosis is a general mechanism in
cancer. Most chemotherapies act by the induction of apoptosis.
Therefore, evasion of apoptosis is mainly responsible for the
insufficiency of current therapies [2,5]. It is well known that cells
can die of apoptosis primarily through the extrinsic death
receptor-induced pathway and/or the intrinsic mitochondria-
mediated pathway [6]. The activation of the extrinsic death
receptor-mediated apoptotic pathway involves ligation of a death
ligand (e.g., tumor necrosis factor-related apoptosis-inducing
ligand; TRAIL) with its corresponding cell surface death
receptor(s) or aggregation (e.g. trimerization) of death receptors,
leading to the formation of the death-inducing signaling complex
(DISC) followed by the activating cleavage of caspase-8 in the
DISC. Because Bid serves as a caspase-8 substrate, activation of
the extrinsic death receptor apoptotic pathway also turns on the
intrinsic apoptotic pathway [7].
The death ligand TRAIL has recently emerged as potential
cancer therapeutic agent because it preferentially induces
apoptosis in transformed or malignant cells [8]. Currently
recombinant human TRAIL is being tested in phase I clinical
trials. Moreover, agonistic antibodies against DR4 and DR5,
which directly activate the extrinsic apoptotic pathway, have also
been tested in phase I or II trials [9]. Thus, the death receptor,
particularly the TRAIL death receptor mediated apoptosis has
been under intense research as a cancer therapeutic target [10,11].
Many preclinical studies have demonstrated therapeutic potential
of targeting the TRAIL/death receptor-mediated apoptosis in
pancreatic cancer [12–20]. However, an important issue in this
regard is the intrinsic resistance of certain cancer cells including
pancreatic cancer cells to TRAIL/death receptor-induced apop-
tosis [17,18].
Cellular FLICE-inhibitory protein (c-FLIP), which inhibits
caspase-8 activation by preventing recruitment of caspase-8 to
DISC, is the primary inhibitor of TRAIL/death receptor-induced
apoptosis [21,22]. The levels of c-FLIP, including both FLIPL and
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10376FLIPS are subject to regulation by ubiquitin/proteasome-mediated
degradation [23–25]. Elevated c-FLIP expression protects cells
from death receptor-mediated apoptosis, whereas downregulation
of c-FLIP by chemicals or small interfering RNA sensitizes cells to
death receptor-mediated apoptosis [26]. Overexpression of c-FLIP
has been suggested to be the key mechanism underlying TRAIL
resistance in pancreatic cancer [13,17].
LBH589 (panobinostat) is a pan-histone deacetylase (HDAC)
inhibitor with promising anticancer activity [27]. Single-agent
activity against pancreatic cancer has been demonstrated in
preclinical experimental models [28]. In this study, we have
revealed a novel activity of LBH589, which sensitizes pancreatic
cancer cells to TRAIL-induced apoptosis. Moreover, we have
shown that LBH589 facilitates ubiqutin/proteasome-mediated c-
FLIP degradation, leading to enhancement of TRAIL-induced
apoptosis in pancreatic cancer.
Materials and Methods
Reagents
LBH589 was provided by Novartis (Basel, Switzerland). The
soluble recombinant human TRAIL was purchased from
PeproTech, Inc. (Rocky Hill, NJ). The proteasome inhibitor
MG132 and the protein synthesis inhibitor cyclohexemide (CHX)
were purchased from Sigma Chemical Co. (St. Louis, MO).
Rabbit polyclonal anti-DR5 antibody was purchased from ProSci
Inc (Poway, CA). Mouse monoclonal anti-DR4 antibody (B-N28)
was purchased from Diaclone (Stamford, CT). Mouse monoclonal
anti-caspase-3 antibody was purchased from Imgenex (San Diego,
CA). Rabbit polyclonal anti-XIAP, anti-caspase-8, anti-Mcl-1, and
anti-PARP antibodies and mouse monoclonal anti-survivin
antibody were purchased from Cell Signaling Technology, Inc.
(Beverly, MA). Mouse anti Bcl-2 antibody was purchased from
Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Rabbit anti-
GAPDH polyclonal antibody and mouse anti-Bax monoclonal
antibody were purchased from Trevigen (Gaithersburg, MD).
Mouse monoclonal anti-b-actin antibody was purchased from
Sigma Chemical Co.
Cell Lines and Cell Culture
Human pancreatic cancer cell lines used in this study were
purchased from the American Type Culture Collection (Manassas,
VA). For establishing pancreatic cancer cell lines that stably
express ectopic c-FLIP or survivin, Panc-1 cells were infected with
lentiviruses harboring lentiviral expression vectors of FLIPL and
survivin, respectively, as described previously [29,30]. We also
infected cells with lentiviruses carrying Lac Z expression vector as
a control [29]. Individual cell clones resistant to blasticidin were
expanded and subjected to screening of the expression of the
targeted protein by Western blotting. These cell lines were
cultured in DMSM medium containing 5% fetal bovine serum
at 37uC in a humidified atmosphere of 5% CO2 and 95% air.
Cell Survival Assay
Cells were seeded in 96-well cell culture plates and treated the
next day with the agents indicated. The viable cell numbers were
determined using the sulforhodamine B (SRB) assay, as previously
described [31]. Combination index for drug interaction (e.g.,
synergy) was calculated using the CompuSyn software (Combo-
Syn, Inc.; Paramus, NJ). The statistical significance of differences
between two treatments was analyzed with two-sided unpaired
student’s t tests by use of Graphpad InStat 3 software (GraphPad
Software, San Diego, CA). Results were considered to be
statistically significant at P,0.05.
Detection of Apoptosis
Apoptosis was evaluated by annexin V staining using annexin
V-PE apoptosis detection kit purchased from BD Biosciences (San
Jose, CA) following the manufacturer’s instructions. We also
detected caspase activation by Western blotting (as described
below) as an additional indicator of apoptosis.
Western Blot Analysis
Whole-cell protein lysates were prepared and analyzed by
Western blotting as described previously [32,33].
Immunoprecipitation for Detection of Ubiqutinated
c-FLIP
Panc-1/FLIPL-5 cells, which stably express FLIPL, were
transfected with HA-ubiquitin plasmid using the FuGENE 6
transfection reagent (Roche Diagnostics Corp., Indianapolis, IN)
following the manufacturer’s instruction. After 24 h, the cells were
treated with LBH589 or MG132 plus LBH589 for 4 h and then
were lysed for immunoprecipitation of Flag-FLIPL using Flag M2
monoclonal antibody (Sigma Chemicals) as previously described
[34] followed by the detection of ubiquitinated FLIPL with
Western blotting using anti-HA antibody (Abgent; San Diego,
CA).
Results
LBH589 Sensitizes Pancreatic Cancer Cells to
TRAIL-induced Apoptosis
We first determined the sensitivities of pancreatic cancer cell
lines used in this study to TRAIL. As presented in Fig. 1A, four
pancreatic cancer cell lines showed differential sensitivities:
MiaPaCa-2 and Bxpc3 exhibited dose-dependent decrease in cell
survival upon TRAIL treatment and thus were sensitive to
TRAIL, whereas Panc-1 and Capan-2 were resistant to TRAIL
because they showed minimal response to TRAIL in terms of
decrease in cell survival. When combined with LBH589, enhanced
cell-killing effects were observed not only in TRAIL-sensitive cells
(e.g., Bcpc-3), but also in TRAIL-resistant cell lines (e.g., Panc-1
and Capan-2) because the combination of LBH589 and TRAIL
were much more than either agent alone in decreasing the survival
of the pancreatic cancer cells (Fig. 1B). The combination indexes
for LBH589 (e.g., 12.5 nM) and TRAIL (3.125–26 ng/ml)
combination in the tested cell lines were ,0.5 (Fig. 1C), indicating
that LBH589 and TRAIL combination exerts synergistic effects on
decreasing cell survival of pancreatic cancer cells. Moreover, we
directly detected apoptosis by measuring annexin V-positive cells
and caspase cleavage in cells exposed to LBH589 alone, TRAIL
alone and their combination. In agreement with cell survival data,
the combination of LBH589 and TRAIL was much more potent
than each single agent alone in inducing cleavage of caspase-9,
caspase-8, caspase-3 and PARP (Fig. 2A) and increasing annexin
V-positive cells (i.e., apoptotic cells) (Fig. 2B). Specifically, LBH589
and TRAIL alone caused approximately 18% and 21% apoptosis,
respectively; however, the combination of LBH589 and TRAIL
induced about 62% apoptosis, which is obviously greater than
additive effect. Collectively, these results indicate that LBH589
sensitize pancreatic cancer cells to TRAIL-induced apoptosis.
LBH589 Decreases the Levels of c-FLIP and Survivin in
Pancreatic Cancer Cells
To understand the mechanisms by which LBH589 sensitizes
pancreatic cancer cell lines to TRAIL-induced apoptosis, we first
analyzed the modulatory effects of LBH589 on c-FLIP, DR5, DR4
LBH589 and TRAIL Combination
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TRAIL/death receptor-mediated apoptosis, in three pancreatic
cancer cell lines. Panc-1 and Capan-2 cells had higher basal levels
of c-FLIP (particularly FLIPL) than Bxpc-3 cells. Treatment of
these cell lines with LBH589 decreased the levels of c-FLIP in all
of the three cell lines in a concentration-dependent manner
(Fig. 3A). The c-FLIP reduction occurred at 3 h and became even
more pronounced at 12 h post and thereafter post LBH589
Figure 1. Responses of human pancreatic cancer cell lines to TRAIL (A) or to the combination of LBH589 and TRAIL (B and C). A, The
indicated cell lines were seeded in 96-well cell culture plates and treated the next day with the given concentrations of TRAIL for 24 h. Cell numbers
were estimated using the SRB assay. Data are the means of four replicate determinations; bars, 6 SDs. *, P,0.01 compare with untreated cells. B, The
indicated cell lines seeded in 96-well cell culture plates were treated with the given concentrations of TRAIL alone, LBH589 alone, or the respective
combination of LBH and TRAIL for 24 h. Cell numbers were estimated using the SRB assay. Data are the means of four replicate determinations; bars,
6 SDs. In Bxpc-3 and Panc-1 cells, each combination is significantly more effective than either TRAIL alone or LBH589 alone in decreasing cell survival
(P,0.05 or ,0.001). In Capan-2 cells, LBH589 at 50 nM in combination with 12.5 ng/ml or 25 ng/ml is significantly more effectively than LBH589 or
TRAIL alone in decreasing cell survival (P,0.001). So are the LBH589 at 25 nM or 50 nM combined with TRAIL (P,0.05). C, Combinations indexes (CIs)
were calculated based on the data presented in Fig. 1B using CompuSyn software.
doi:10.1371/journal.pone.0010376.g001
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either of the tested cell lines (Fig. 3A) and only minimally increased
DR5 expression in one of the three tested cell lines (i.e., Bxpc-3)
(Figs. 3A and 3B). These results clearly suggest that c-FLIP
donwregulation is an important event induced by LBH589.
In addition, we also examined the modulatory effects of
LBH589 on other proteins including survivin, XIAP, Bcl-2, Mcl-
1, and Bax, which regulate the mitochondria-mediated apoptosis.
LBH589 decreased survivin levels in Panc-1 and Capan-2 cells,
but not Bxpc-3 cells (Fig. 3A). Time course analysis of survivin
levels in Panc-1 cells demonstrated that the pronounced survivin
reduction occurred at 12 h post LBH589 treatment (Fig. 3B).
LBH589 did not alter the levels of Bax and XIAP in these cell
lines; however, it increased the levels of Mcl-2 in these cell lines as
well as Bcl-2 levels in Bxpc-3 cells (Fig. 2A). Together, these results
also suggest that survivin reduction may also be an important
event induced by LBH589.
Enforced Expression of Ectopic c-FLIP, but not Survivin,
Protects Cells from Induction of Apoptosis by the
Combination of LBH569 and TRAIL
Both c-FLIP and survivin are involved in regulation of TRAIL
cell sensitivity [35]. To determine the involvement of c-FLIP and
survivindownregulationin sensitization of pancreatic cancer cells to
TRAIL-induced apoptosis by LBH589, we established Panc-1 cell
lines that stably expressed ectopic FLPL or survivin through a
lentivial expression system and then examined their responses to the
combination of LBH589 and TRAIL. The expression of ectopic
survivin or c-FLIP was assumed by Western blotting as presented in
Fig. 4A. Lac Z is an irrelevant protein and here was used as a
control. As demonstrated above, the combination of LBH589 and
TRAIL effectively decreased cell survival in Lac Z- or survivin-
expressing cell lines, but failed to do so in both cell lines that express
ectopic FLIPL (Fig. 4B), indicating the enforced expression of
ectopic FLIPL, rather than survivin, confers cell resistance to
augmented induction of apoptosis by LBH589 and TRAIL
combination. By detecting apoptosis, we found that the combina-
tion of LBH589 strongly induced cleavage of caspase-8, caspase-9,
caspase-3 and PARP in panc-1 cell lines that express Lac Z or
survivin, but only minimally in FLIPL-expressing Panc-1 cells
(Fig. 5A). In agreement, the combination of LBH589 and TRAIL
caused approximately 79% and 69% of apoptosis in Panc-1/lac Z-1
and Panc-1/survivin-4 cells, respectively, but only about 25% of
apoptosis in Panc-1/FLIPL-5 cells (Fig. 5B), further confirming that
FLIPL overexpression confers cell resistance to the combination of
LBH589 and TRAIL. Collectively, these results demonstrate that c-
FLIP downregulation plays a key role in LBH-589-mediated
sensitizationofpancreaticcancercellstoTRAIL-induced apoptosis.
Figure 2. The LBH589 and TRAIL combination augments caspase activation (A) and apoptosis (B). A, The indicated cell lines were treated
with DMSO control, 50 nM LBH589 25 ng/ml TRAIL alone, or LBH589 plus TRAIL. After 16 h, the cells were subjected to preparation of whole-cell
protein lysates for detecting caspase cleavage using Western blotting. Casp, caspase; CF, cleaved fragment. B, Panc-1 cells were treated with 25 ng/
ml TRAIL alone, 50 nM LBH589 alone or their combination for 24 h. The cells were then subjected to measurement of apoptosis using annexin V
staining. The percent positive cells in the upper right and lower right quadrants represent the total apoptotic cell population.
doi:10.1371/journal.pone.0010376.g002
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Ubiqitin/proteasome-mediated Degradation
Given the critical role of c-FLIP downregulation in mediating
enhancement of TRAIL-induced apoptosis by LBH589 as
demonstrated above, we further addressed how LBH589 decreased
c-FLIPlevels.Becausec-FLIPproteinsareknowntoberegulatedby
ubiquitin/proteasome-mediated degradation [23,25], we then
determined whether the observed downregulation of c-FLIP by
Figure 3. LBH589 modulates the levels of c-FLIP, survivin and
other apoptosis-related proteins. The given cell lines were treated
with different concentrations of LBH589 as indicated for 12 h (A) or with
50 nM LBH589 for the indicated times (B). After the treatments, the cell
lines were subjected to preparation of whole-cell protein lysates and
subsequent Western blot analysis for detection of the indicated
proteins.
doi:10.1371/journal.pone.0010376.g003 Figure 4. Enforced expression of ectopic c-FLIP, but not
survivin (A), confers cell resistance to cell-killing by LBH589
and TRAIL combination (B). A, The expression of ectopic survivin or
c-FLIP in the various trasnfectants as indicated was detected by Western
blotting with survivin or c-FLIP antibody. B, The given transfectants
were seeded in 96-well plates and treated with the indicated
concentrations of LBH589 alone, 25 ng/ml TRAIL alone, or individual
combination of LBH589 with TRAIL. After 24 h, the cells were subjected
to the SRB assay for measurement of cell survival. Data are the means of
four replicate determinations; bars; 6 SDs. *, P,0.0001 and #, P,0.001
compared with LBH589 treatment alone.
doi:10.1371/journal.pone.0010376.g004
LBH589 and TRAIL Combination
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examined whether LBH589 promotes c-FLIP degradation. To this
end, we treated Panc-1cells with either DMSO or LBH589 for 4 h
and then washed away the drug followed by refilling the cells with
fresh medium containing the protein synthesis inhibitor CHX. At
the indicated times post CHX, the cells were harvested for Western
blottingtoanalyzec-FLIPdegradationrate.AspresentedinFig.6A,
the reduction or degradation rate of FLIPL in LBH589-treated cells
was apparently faster than that in DMSO-treated control cells,
indicating that LBH589 indeed facilitates c-FLIP degradation.
Next, we treated cells with LBH589 in the absence and presence of
the proteasome inhibitor MG132 and then compared c-FLIP
modulation under these conditions. As presented in Fig. 6B,
LBH589 decreased c-FLIP levels in the absence of MG132, but not
inthe presence ofMG132,suggestingthat LBH589-induced c-FLIP
degradation is proteasome-dependent. By immunoprecipitation/
Western blotting, we also detected the highest levels of ubiqutinated
FLIPL in cells treated with LBH589 plus MG132 compared to cells
exposed to LBH589 alone or MG132 alone (Fig. 6C), indicating
that HNK increases c-FLIP ubiquitination. Taken together, we
conclude that LBH589 induces ubiquitin/proteasome-mediated c-
FLIP degradation, leading to downregulation of c-FLIP in human
pancreatic cancer cells.
Discussion
Human pancreatic cancer tumors or cell lines exhibit
heterogeneous responses to TRAIL. Some of these tumors or cell
lines are intrinsically insensitive to TRAIL-induced apoptosis
[17,18]. In this study, we have presented a novel finding that the
histone deacetylase inhibitor LBH589 effectively augments
TRAIL-induced apoptosis in human pancreatic cancer cells
including those resistant to TRAIL-induced apoptosis. Given that
LBH589 shows anticancer activity in preclinical pancreatic cancer
models [28] as well that the tumor-selective TRAIL is a potential
cancer therapeutic protein and is being tested in phase I clinical
trials, our findings warrant further evaluation on the combination
of LBH589 and TRAIL as a potential therapeutic regimens
against pancreatic cancer in animal models and in clinical trials.
Both survivin and XIAP are suggested to regulate TRAIL-
mediated apoptosis [12,36,37]. Some HDAC inhibitors such as
sodium butyrate and LAQ824 were reported to augment TRAIL-
induced apoptosis involving donwregualtion of survivin and XIAP
[38,39]. A recent study has suggested that LBH589 enhances
TRAIL-induced apoptosis through downregulation of XIAP in
mesothelioma cells [40]. In our study, we found that LBH589
decreased survivin levels in two (i.e., Panc-1 and Capan-2) of three
tested pancreatic cancer cell lines but did not obviously alter the
levels of XIAP (Fig. 3). Moreover, enforced expression of ectopic
survivin did not confer resistance to LBH589/TRAIL-induced
apoptosis (Figs. 4 and 5). Thus, survivin and XIAP are unlikely to
be involved in regulation of LBH589-mediated sensitization of
TRAIL-induced apoptosis in pancreatic cancer cells.
Bcl-2 family members such as Bcl-2 and Mcl-1 have also been
suggested in regulation of TRAIL-induced apoptosis [14,35].
Figure 5. Enforced expression of ectopic c-FLIP, but not survivin, confers cell resistance to caspase activation (A) and apoptosis (B)
induced by the LBH589 and TRAIL combination. The indicated transfectants were treated without and with 50 nM LBH589 plus 25 ng/ml
TRAIL (L/T) for 16 h (A)o r2 4h( B). The cells were then harvested for preparation of whole-cell protein lysates for detecting caspase and PARP
cleavage using Western blotting (A) or for measurement of apoptosis using annexin V staining (B). The percent positive cells in the upper right and
lower right quadrants represent the total apoptotic cell population.
doi:10.1371/journal.pone.0010376.g005
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different cancer cells involving modulation of Bcl-2 family
members such as downregulation of Bcl-2 and Bcl-XL and
upregulation of Bax and Bim [39,41–44]. In our study, LBH589
did not change Bax levels. Unexpectedly, LBH589 increased the
levels of Bcl-2 and Mcl-1 (Fig. 3). Thus, the modulation of these
proteins is unlikely to be associated with LBH589-mediated
potentiation of TRAIL-induced apoptosis in these cell lines;
rather, increase in Bcl-2 and Mcl-1 may counteract LBH589’s
effect in sensitizing pancreatic cancer cells to TRAIL-induced
apoptosis. Thus, further inclusion of a Bcl-2 or Mcl-1 inhibitor to
this regimen may result in even more efficacious anticancer
efficacy than the combination of LBH589 and TRAIL and should
be further explored.
DR5 induction and c-FLIP downregulation are important
mechanisms underlying drug-mediated augmentation or sensiti-
zation of TRAIL-induced apoptosis [45]. In our study, we found
that LBH589 either did not or only weakly increased DR5
expression in pancreatic cancer cell lines (Fig. 3), suggesting that
DR5 modulation has a limited role in LBH589-mediated
sensitization of TRAIL-induced apoptosis in these cells. c-FLIP
levels have been suggested to be associated with the sensitivity of
pancreatic cancer cells to TRAIL-induced apoptosis; specifically,
higher levels of c-FLIP was detected in the TRAIL-resistant
pancreatic cancer cell lines compared with the TRAIL sensitive
cells [17]. Inhibition of c-FLIP with a small interfering RNA or a
small molecule sensitizes pancreatic cancer cells to TRAIL-
induced apoptosis [13,17]. Moreover, other HDAC inhibitors
such as LAQ824, MS-275, FR901228, valproic acid and
droxinostat have been shown to downregulate c-FLIP levels and
enhance death receptor-induced apoptosis [46–52]. In our study,
we also found that the TRAIL-resistant cell lines Panc-1 and
Capan-2 had higher basal levels of c-FLIP than the TRAIL-
sensitive cell line (Bxpc-3) (Fig. 3A). Like other HDAC inhibitors,
LBH589 decreased c-FLIP cell lines in these three tested cell lines;
this c-FLIP downregulation is a rapid event because c-FLIP
reduction was detected even at 3 h post LBH589 treatment (Fig. 3).
Importantly, enforced expression of ectopic c-FLIP (i.e., FLIPL)
abolished LBH589’s ability to enhance TRAIL-induced apoptosis
(Figs. 4 and 5). Collectively, these results indicate that downreg-
Figure 6. LBH589 reduces c-FLIP levels through ubiquitin/proteasome-mediated protein degradation. A, Panc-1 cells were treated with
DMSO or 50 nM LBH589 for 4 h. The cells were then washed with PBS 3 times and refed with fresh medium containing 10 mg/ml CHX. At the
indicated times post CHX, the cells were harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis. Protein levels
were quantitated with NIH Image J software (Bethesda, MA) and were normalized to GAPGH. The results were plotted as the relative c-FLIP levels
compared to those at the time 0 of CHX treatment (lower panel). B, Panc-1 cells were pretreated with 20 mM MG132 for 30 minutes prior to the
addition of 50 nM LBH589. After co-treatment for 4 h, the cells were harvested for preparation of whole-cell protein lysates and subsequent Western
blot analysis. C, Panc-1/FLIPL-5 cells which stably express ectopic flag-FLIPL were transfected with HA-ubiquitin plasmid using FuGENE 6 transfection
reagent for 24 h. The cells were then pretreated with 20 mM MG132 for 30 minutes and then co-treated with 50 nM LBH589 for 4 h. Whole-cell
protein lysates were then prepared for immunoprecipitation (IP) using anti-Flag antibody followed by Western blotting (WB) using anti-HA antibody
for detection of ubiquitinated FLIPL (Ub-FLIPL) and anti-Flag antibody for detection of ectopic FLIPL.
doi:10.1371/journal.pone.0010376.g006
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pancreatic cancer cells to TRAIL-induced apoptosis.
c-FLIP is known to be regulated by ubiquitin/proteasome-
mediated degradation [23,24]. Previous studies have shown that c-
FLIP downregulation induced by certain HDAC inhibitors occurs
at mRNA level [39,51]. How HDAC inhibitors downregulate c-
FLIP levels has not been fully elucidated. In our study, we found
that LBH589 facilitated c-FLIP degradation as demonstrated in
CHX chase assay. The presence of the proteasome inhibitor
MG132 prevented c-FLIP from reduction induced by LBH589.
Moreover, LBH589 increased the levels of ubiquitinated c-FLIP
(Fig. 6). Thus, these results indicate that LBH589 facilitates
ubqitin/proteasome-mediated c-FLIP degradation, resulting in c-
FLIP downregulation. To the best of our knowledge, the finding
on c-FLIP degradation or downregulation by LBH589 is novel
and warrants further investigation on how inhibition of histone
deacetylase leads to c-FLIP degradation.
The maximal plasma concentrations of LBH589 in human
cancer patients range from 200 nM to 1300 nM depending on
doses tested [53]. The concentrations of LBH589 used in our study
that downregulate c-FLIP and enhance TRAIL-induced apoptosis
are between 12.5 nM and 100 nM and thus within clinically
achievable range. Therefore, the future clinical test of the
combination is warranted.
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